Cancer Drug Market by Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy), by Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other) - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Cancer Drug Market

Industry:  Life Sciences & Healthcare | Publish Date: Aug 2020 | No of Pages:  385 | No. Tables:  214 | No. Figures:  184

Market Definition

The global Cancer Drug Market size was valued at USD 112.73 billion in 2019, and is predicted to reach USD 215.11 billion by 2030, with a CAGR of 5.9%, from 2020-2030.

Cancer is a chronic disease that tends to initiate abnormal growth of cells, leading to the formation of tumors, that have the tendency to propagate throughout the lymphatic system, blood, and tissues in the human body. Conversely, benign tumors are non-cancerous tumors. There are different types of cancers like lung cancer, stomach cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, renal cancer, bladder cancer, and other. Cancer can be diagnosed with the help of various clinical investigations such as CT scans, blood tests, biopsy, and others diagnostic options. In the early stages of cancer, chemotherapy is used as first-line treatment, and for chronic cancer diseases targeted therapy, immunotherapy as well as a combination of different therapies is used as treatment options.

The leading behavioral and dietary risks such as, obesity, lack of physical activity, nutrient deficiency due to food habits, sedentary lifestyles, and higher consumption of alcohol & tobacco, are leading to higher prevalence of cancer worldwide; shall consequently propagate the growth of cancer drug market, in coming future.

Market Dynamics and Trends

Cancer caused nearly 9.6 million deaths in 2018, and it is the second-leading cause of death world-wide; according to the data provided by the World Health Organization. At the global level, about 1 in 6 deaths are due to cancer. This market scenario is responsible for creating new avenues for growth in the global cancer drug market.

However, the cost-effectiveness of cancer drugs along with their side effects are expected to adversely affect the global cancer drug industry growth.

Moreover, factors such as, increase in number of geriatric population, rising awareness about cancer treatment options, increasing investments in R&D activities regarding formulation of potent cancer drugs, advancements in product technologies as well as untapped market opportunities offered by emerging economies, are to create lucrative opportunities in the global cancer drug market, in coming future.

 

Market Segmentations and Scope of the Study

The global cancer drug market report has been analyzed based on drug class, indication and geography. Based on drug class, the global market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy. Based on indication, the market is divided into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

 

Geographical Analysis

North America dominated the global cancer drug market share in the past and is expected to maintain its dominance throughout the forecast period. This is attributed to well-established healthcare infrastructure, presence of specialized medical practitioners & surgeons, advancements in product technologies, increasing inclination towards sedentary lifestyles and easy access to premium chemotherapy treatments in this region.

Asia Pacific region is expected to witness a substantial growth in the global market throughout the forecast period, witnessing the highest CAGR values. Factors responsible for boosting the cancer drug market growth in this region are, improving healthcare infrastructures, growing consumer awareness about different cancer treatment options, increasing investment in R&D activities, raise in per-capita disposable incomes, as well as untapped market opportunities offered by the emerging economies present in this region.

 

Competitive Landscape

The cancer drug industry is highly competitive and consists of various market players. Some of the major market players include Astellas Pharma Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, f. Hoffmann-La Roche ltd., Celgene Corporation, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC,), Pfizer Inc., and Novartis AG among others.

An upsurge in R&D activities and advancement in product technologies along with new product launches by the key players, is leading the healthcare infrastructure to new heights, thereby creating lucrative opportunities in the global cancer drug market.

For instance, in September 2019, a clinical trial study demonstrated that patients receiving Bristol-Myers Squibb’s immuno-oncology drugs OPDIVO and YERVOY as an initial treatment for advanced non-small cell lung cancer had longer life-span as compared to those undergoing normal chemotherapy.

In December 2019, Adaptimmune Therapeutics Plc., a pioneer in T-cell cancer treatment therapy and one of the major players in the global cancer drug market, announced that it has received RMAT (Regenerative Medicine Advanced Therapy) designation from the US Food and Drug Administration (FDA), for its ‘ADP A2M4,’ a therapeutic treatment for synovial sarcoma. In the same year ADP-A2M4 was granted ODD (Orphan Drug Designation) for the treatment of soft tissue sarcomas by the US FDA. RMAT opens the door for commercialization of ADP-A2M4, that shall enter the market by 2022.

Furthermore, in January 2020, Merck, a leading company in the global market, announced that it has achieved U.S. Food and Drug Administration approval for its ‘anti-PD-1 therapy,’ monotherapy for the treatment of patients suffering from Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS), with or without papillary tumors, for whom undergo cystectomy is not a feasible option or is not advisable. KEYTRUDA is a drug that can be used in combination with various drugs to treat different types of cancer. Traditionally, for the patients suffering from BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with CIS, there were limited non-surgical treatment options, but Merk’s KEYTRUDA proves to be a ray of hope encouraging the medical practitioners with new treatment option in the industry.

Key Benefits

  • The cancer drug market report provides a quantitative analysis of the current market and estimations through 2020-2030 that assist in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the cancer drug market trend including the current and future trends for depicting the prevalent investment pockets in the market.

  • The report provides detailed information related to key drivers, restraints and opportunities and their impact on the market.

  • The report incorporates competitive analysis of the market players along with their market share in the global market.

  • The SWOT analysis and Porters Five Forces model is elaborated in the study of the global market.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

Cancer Drug Market Key Segments

By Drug Class

  • Chemotherapy

  • Targeted Therapy

  • Immunotherapy (Biologic Therapy)

  • Hormonal Therapy

By Indication

  • Lung Cancer

  • Stomach Cancer

  • Colorectal Cancer

  • Breast Cancer

  • Prostate Cancer

  • Liver Cancer

  • Esophagus Cancer

  • Cervical Cancer

  • Kidney Cancer

  • Bladder Cancer

  • Other

By Geography

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • Spain

    • France

    • Italy

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Rest of Asia-Pacific

  • RoW

    • Saudi Arabia

    • South Africa

    • Brazil

    • Remaining countries

Report Scope and Segmentation

Parameters

Details

Analysis Period

2019–2030

Base Year Considered

2020

Forecast Period

2020–2030

Market Size Estimation

Billion (USD)

Market Segmentation

By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy) By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer)

Geographical Segmentation

North America (U.S., Canada, Mexico) Europe (Germany, UK, Spain, France, Italy, Rest of Europe), Asia-Pacific (Australia, China, India, Japan, South Korea, Rest of APAC) Rest of World (Brazil, Saudi Arabia, South Africa, Remaining Countries)

Companies Profiled

Astellas Pharma Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, f. Hoffmann-La Roche ltd., Celgene Corporation, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC,), Pfizer Inc., and Novartis AG.
column chart pie chart

Test

1. INTRODUCTION

1.1.           REPORT DESCRIPTION

1.2.           RESEARCH METHODOLOGY

1.2.1             SECONDARY RESEARCH

1.2.2             DATA ANALYSIS FRAMEWORK

1.2.3             MARKET SIZE ESTIMATION

1.2.4             FORECASTING

1.2.5             PRIMARY RESEARCH AND DATA VALIDATION

2. MARKET SNAPSHOT, 2022-2030 MILLION USD

2.1.           MARKET SNAPSHOT

3. PORTER’S FIVE FORCE MODEL ANALYSIS

4. MARKET DYNAMICS

4.1.           GROWTH DRIVERS

4.1.1             DRIVER 1

4.1.2             DRIVER 2

4.1.3             DRIVER 3

4.1.4             DRIVER 4

4.2.           CHALLENGES

4.2.1             CHALLENGE 1

4.2.2             CHALLENGE 2

4.3.           OPPORTUNITIES

4.3.1             OPPORTUNITY 1

4.3.2             OPPORTUNITY 2

5. GLOBAL  CANCER DRUGS MARKET, BY DRUG CLASS TYPE

5.1.           OVERVIEW

5.2.           CHEMOTHERAPY

5.2.1             CHEMOTHERAPY MARKET, BY REGION

5.2.1.1        NORTH AMERICA CHEMOTHERAPY MARKET, BY COUNTRY

5.2.1.2        EUROPE CHEMOTHERAPY MARKET, BY COUNTRY

5.2.1.3        ASIA-PACIFIC CHEMOTHERAPY MARKET, BY COUNTRY

5.2.1.4        REST OF WORLD CHEMOTHERAPY MARKET, BY COUNTRY

5.3.           TARGETED THERAPY

5.3.1             TARGETED THERAPY MARKET, BY REGION

5.3.1.1        NORTH AMERICA TARGETED THERAPY MARKET, BY COUNTRY

5.3.1.2        EUROPE TARGETED THERAPY MARKET, BY COUNTRY

5.3.1.3        ASIA-PACIFIC TARGETED THERAPY MARKET, BY COUNTRY

5.3.1.4        REST OF WORLD TARGETED THERAPY MARKET, BY COUNTRY

5.4.           IMMUNOTHERAPY

5.4.1             IMMUNOTHERAPY MARKET, BY REGION

5.4.1.1        NORTH AMERICA IMMUNOTHERAPY MARKET, BY COUNTRY

5.4.1.2        EUROPE IMMUNOTHERAPY MARKET, BY COUNTRY

5.4.1.3        ASIA-PACIFIC IMMUNOTHERAPY MARKET, BY COUNTRY

5.4.1.4        REST OF WORLD IMMUNOTHERAPY MARKET, BY COUNTRY

5.5.           HORMONAL THERAPY

5.5.1             HORMONAL THERAPY MARKET, BY REGION

5.5.1.1        NORTH AMERICA HORMONAL THERAPY MARKET, BY COUNTRY

5.5.1.2        EUROPE HORMONAL THERAPY MARKET, BY COUNTRY

5.5.1.3        ASIA-PACIFIC HORMONAL THERAPY MARKET, BY COUNTRY

5.5.1.4        REST OF WORLD HORMONAL THERAPY MARKET, BY COUNTRY

5.6.

5.6.1             GLOBAL 0 MARKET, BY DRUG CLASS TYPE

5.6.1.1        PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY REGION

5.6.1.1.1        NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.1.2        EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.1.3        ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.1.4        REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.2        CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY REGION

5.6.1.2.1        NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.2.2        EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.2.3        ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.2.4        REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.3        CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY REGION

5.6.1.3.1        NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.3.2        EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.3.3        ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

5.6.1.3.4        REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY

6. GLOBAL  CANCER DRUGS MARKET, BY INDICATION

6.1.           OVERVIEW

6.2.           LUNG CANCER

6.2.1             LUNG CANCER MARKET, BY REGION

6.2.1.1        NORTH AMERICA LUNG CANCER MARKET, BY COUNTRY

6.2.1.2        EUROPE LUNG CANCER MARKET, BY COUNTRY

6.2.1.3        ASIA-PACIFIC LUNG CANCER MARKET, BY COUNTRY

6.2.1.4        REST OF WORLD LUNG CANCER MARKET, BY COUNTRY

6.3.           STOMACH CANCER

6.3.1             STOMACH CANCER MARKET, BY REGION

6.3.1.1        NORTH AMERICA STOMACH CANCER MARKET, BY COUNTRY

6.3.1.2        EUROPE STOMACH CANCER MARKET, BY COUNTRY

6.3.1.3        ASIA-PACIFIC STOMACH CANCER MARKET, BY COUNTRY

6.3.1.4        REST OF WORLD STOMACH CANCER MARKET, BY COUNTRY

6.4.           COLORECTAL CANCER

6.4.1             COLORECTAL CANCER MARKET, BY REGION

6.4.1.1        NORTH AMERICA COLORECTAL CANCER MARKET, BY COUNTRY

6.4.1.2        EUROPE COLORECTAL CANCER MARKET, BY COUNTRY

6.4.1.3        ASIA-PACIFIC COLORECTAL CANCER MARKET, BY COUNTRY

6.4.1.4        REST OF WORLD COLORECTAL CANCER MARKET, BY COUNTRY

6.5.           BREAST CANCER

6.5.1             BREAST CANCER MARKET, BY REGION

6.5.1.1        NORTH AMERICA BREAST CANCER MARKET, BY COUNTRY

6.5.1.2        EUROPE BREAST CANCER MARKET, BY COUNTRY

6.5.1.3        ASIA-PACIFIC BREAST CANCER MARKET, BY COUNTRY

6.5.1.4        REST OF WORLD BREAST CANCER MARKET, BY COUNTRY

6.6.           PROSTATE CANCER

6.6.1             PROSTATE CANCER MARKET, BY REGION

6.6.1.1        NORTH AMERICA PROSTATE CANCER MARKET, BY COUNTRY

6.6.1.2        EUROPE PROSTATE CANCER MARKET, BY COUNTRY

6.6.1.3        ASIA-PACIFIC PROSTATE CANCER MARKET, BY COUNTRY

6.6.1.4        REST OF WORLD PROSTATE CANCER MARKET, BY COUNTRY

6.7.           LIVER CANCER

6.7.1             GLOBAL LIVER CANCER MARKET, BY INDICATION

6.7.1.1        HOSPITAL ACQUIRED PNEUMONIA MARKET, BY REGION

6.7.1.1.1        NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY

6.7.1.1.2        EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY

6.7.1.1.3        ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY

6.7.1.1.4        REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY

6.7.1.2        VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY REGION

6.7.1.2.1        NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY

6.7.1.2.2        EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY

6.7.1.2.3        ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY

6.7.1.2.4        REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY

6.7.1.3        OTHER NOSOCOMIAL PNEUMONIA MARKET, BY REGION

6.7.1.3.1        NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.1.3.2        EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.1.3.3        ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.1.3.4        REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY

6.7.2             LIVER CANCER MARKET, BY REGION

6.7.2.1        NORTH AMERICA LIVER CANCER MARKET, BY COUNTRY

6.7.2.2        EUROPE LIVER CANCER MARKET, BY COUNTRY

6.7.2.3        ASIA-PACIFIC LIVER CANCER MARKET, BY COUNTRY

6.7.2.4        REST OF WORLD LIVER CANCER MARKET, BY COUNTRY

6.8.           ESOPHAGUS CANCER

6.8.1             ESOPHAGUS CANCER MARKET, BY REGION

6.8.1.1        NORTH AMERICA ESOPHAGUS CANCER MARKET, BY COUNTRY

6.8.1.2        EUROPE ESOPHAGUS CANCER MARKET, BY COUNTRY

6.8.1.3        ASIA-PACIFIC ESOPHAGUS CANCER MARKET, BY COUNTRY

6.8.1.4        REST OF WORLD ESOPHAGUS CANCER MARKET, BY COUNTRY

6.9.           CERVICAL CANCER

6.9.1             CERVICAL CANCER MARKET, BY REGION

6.9.1.1        NORTH AMERICA CERVICAL CANCER MARKET, BY COUNTRY

6.9.1.2        EUROPE CERVICAL CANCER MARKET, BY COUNTRY

6.9.1.3        ASIA-PACIFIC CERVICAL CANCER MARKET, BY COUNTRY

6.9.1.4        REST OF WORLD CERVICAL CANCER MARKET, BY COUNTRY

6.10.         KIDNEY CANCER

6.10.1           KIDNEY CANCER MARKET, BY REGION

6.10.1.1      NORTH AMERICA KIDNEY CANCER MARKET, BY COUNTRY

6.10.1.2      EUROPE KIDNEY CANCER MARKET, BY COUNTRY

6.10.1.3      ASIA-PACIFIC KIDNEY CANCER MARKET, BY COUNTRY

6.10.1.4      REST OF WORLD KIDNEY CANCER MARKET, BY COUNTRY

6.11.         BLADDER CANCER

6.11.1           BLADDER CANCER MARKET, BY REGION

6.11.1.1      NORTH AMERICA BLADDER CANCER MARKET, BY COUNTRY

6.11.1.2      EUROPE BLADDER CANCER MARKET, BY COUNTRY

6.11.1.3      ASIA-PACIFIC BLADDER CANCER MARKET, BY COUNTRY

6.11.1.4      REST OF WORLD BLADDER CANCER MARKET, BY COUNTRY

7. GLOBAL  CANCER DRUGS MARKET, BY REGION

7.1.           OVERVIEW

7.2.           NORTH AMERICA

7.2.1             NORTH AMERICA CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.2.2             NORTH AMERICA CANCER DRUGS MARKET, BY INDICATION

7.2.2.1        NORTH AMERICA  LIVER CANCER MARKET, BY INDICATION

7.2.3             NORTH AMERICA CANCER DRUGS, MARKET BY COUNTRY

7.2.3.1        U.S.

7.2.3.1.1        U.S. CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.2.3.1.2        U.S. CANCER DRUGS MARKET, BY INDICATION

7.2.3.1.2.1. U.S. LIVER CANCER MARKET, BY INDICATION

7.2.3.2        CANADA

7.2.3.2.1        CANADA CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.2.3.2.2        CANADA CANCER DRUGS MARKET, BY INDICATION

7.2.3.2.2.1. CANADA LIVER CANCER MARKET, BY INDICATION

7.2.3.3        MEXICO

7.2.3.3.1        MEXICO CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.2.3.3.2        MEXICO CANCER DRUGS MARKET, BY INDICATION

7.2.3.3.2.1. MEXICO LIVER CANCER MARKET, BY INDICATION

7.3.           EUROPE

7.3.1             EUROPE CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.3.2             EUROPE CANCER DRUGS MARKET, BY INDICATION

7.3.2.1        EUROPE  LIVER CANCER MARKET, BY INDICATION

7.3.3             EUROPE CANCER DRUGS, MARKET BY COUNTRY

7.3.3.1        GERMANY

7.3.3.1.1        GERMANY CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.3.3.1.2        GERMANY CANCER DRUGS MARKET, BY INDICATION

7.3.3.1.2.1. GERMANY LIVER CANCER MARKET, BY INDICATION

7.3.3.2        UK

7.3.3.2.1        UK CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.3.3.2.2        UK CANCER DRUGS MARKET, BY INDICATION

7.3.3.2.2.1. UK LIVER CANCER MARKET, BY INDICATION

7.3.3.3        FRANCE

7.3.3.3.1        FRANCE CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.3.3.3.2        FRANCE CANCER DRUGS MARKET, BY INDICATION

7.3.3.3.2.1. FRANCE LIVER CANCER MARKET, BY INDICATION

7.3.3.4        SPAIN

7.3.3.4.1        SPAIN CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.3.3.4.2        SPAIN CANCER DRUGS MARKET, BY INDICATION

7.3.3.4.2.1. SPAIN LIVER CANCER MARKET, BY INDICATION

7.3.3.5        ITALY

7.3.3.5.1        ITALY CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.3.3.5.2        ITALY CANCER DRUGS MARKET, BY INDICATION

7.3.3.5.2.1. ITALY LIVER CANCER MARKET, BY INDICATION

7.3.3.6        REST OF EUROPE

7.3.3.6.1        REST OF EUROPE CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.3.3.6.2        REST OF EUROPE CANCER DRUGS MARKET, BY INDICATION

7.3.3.6.2.1. REST OF EUROPE LIVER CANCER MARKET, BY INDICATION

7.4.           ASIA-PACIFIC

7.4.1             ASIA-PACIFIC CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.4.2             ASIA-PACIFIC CANCER DRUGS MARKET, BY INDICATION

7.4.2.1        ASIA-PACIFIC  LIVER CANCER MARKET, BY INDICATION

7.4.3             ASIA-PACIFIC CANCER DRUGS, MARKET BY COUNTRY

7.4.3.1        JAPAN

7.4.3.1.1        JAPAN CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.4.3.1.2        JAPAN CANCER DRUGS MARKET, BY INDICATION

7.4.3.1.2.1. JAPAN LIVER CANCER MARKET, BY INDICATION

7.4.3.2        INDIA

7.4.3.2.1        INDIA CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.4.3.2.2        INDIA CANCER DRUGS MARKET, BY INDICATION

7.4.3.2.2.1. INDIA LIVER CANCER MARKET, BY INDICATION

7.4.3.3        CHINA

7.4.3.3.1        CHINA CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.4.3.3.2        CHINA CANCER DRUGS MARKET, BY INDICATION

7.4.3.3.2.1. CHINA LIVER CANCER MARKET, BY INDICATION

7.4.3.4        SOUTH KOREA

7.4.3.4.1        SOUTH KOREA CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.4.3.4.2        SOUTH KOREA CANCER DRUGS MARKET, BY INDICATION

7.4.3.4.2.1. SOUTH KOREA LIVER CANCER MARKET, BY INDICATION

7.4.3.5        AUSTRALIA

7.4.3.5.1        AUSTRALIA CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.4.3.5.2        AUSTRALIA CANCER DRUGS MARKET, BY INDICATION

7.4.3.5.2.1. AUSTRALIA LIVER CANCER MARKET, BY INDICATION

7.4.3.6        REST OF ASIA-PACIFIC

7.4.3.6.1        REST OF ASIA-PACIFIC CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.4.3.6.2        REST OF ASIA-PACIFIC CANCER DRUGS MARKET, BY INDICATION

7.4.3.6.2.1. REST OF ASIA-PACIFIC LIVER CANCER MARKET, BY INDICATION

7.5.           REST OF WORLD

7.5.1             REST OF WORLD CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.5.2             REST OF WORLD CANCER DRUGS MARKET, BY INDICATION

7.5.2.1        REST OF WORLD  LIVER CANCER MARKET, BY INDICATION

7.5.3             REST OF WORLD CANCER DRUGS, MARKET BY COUNTRY

7.5.3.1        BRAZIL

7.5.3.1.1        BRAZIL CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.5.3.1.2        BRAZIL CANCER DRUGS MARKET, BY INDICATION

7.5.3.1.2.1. BRAZIL LIVER CANCER MARKET, BY INDICATION

7.5.3.2        SAUDI ARABIA

7.5.3.2.1        SAUDI ARABIA CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.5.3.2.2        SAUDI ARABIA CANCER DRUGS MARKET, BY INDICATION

7.5.3.2.2.1. SAUDI ARABIA LIVER CANCER MARKET, BY INDICATION

7.5.3.3        SOUTH AFRICA

7.5.3.3.1        SOUTH AFRICA CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.5.3.3.2        SOUTH AFRICA CANCER DRUGS MARKET, BY INDICATION

7.5.3.3.2.1. SOUTH AFRICA LIVER CANCER MARKET, BY INDICATION

7.5.3.4        REMAINING COUNTRIES

7.5.3.4.1        REMAINING COUNTRIES CANCER DRUGS MARKET, BY DRUG CLASS TYPE

7.5.3.4.2        REMAINING COUNTRIES CANCER DRUGS MARKET, BY INDICATION

7.5.3.4.2.1. REMAINING COUNTRIES LIVER CANCER MARKET, BY INDICATION

8. COMPANY PROFILES

8.1.           ABBVIE INC.

8.1.1             COMPANY OVERVIEW

8.1.2             COMPANY SNAPSHOT

8.1.3             OPERATING BUSINESS SEGMENTS

8.1.4             PRODUCT PORTFOLIO

8.1.5             BUSINESS PERFORMANCE

8.1.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.2.           ASTELLAS PHARMA INC.

8.2.1             COMPANY OVERVIEW

8.2.2             COMPANY SNAPSHOT

8.2.3             OPERATING BUSINESS SEGMENTS

8.2.4             PRODUCT PORTFOLIO

8.2.5             BUSINESS PERFORMANCE

8.2.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.3.           ASTRAZENECA PLC

8.3.1             COMPANY OVERVIEW

8.3.2             COMPANY SNAPSHOT

8.3.3             OPERATING BUSINESS SEGMENTS

8.3.4             PRODUCT PORTFOLIO

8.3.5             BUSINESS PERFORMANCE

8.3.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.4.           BRISTOL-MYERS SQUIBB COMPANY

8.4.1             COMPANY OVERVIEW

8.4.2             COMPANY SNAPSHOT

8.4.3             OPERATING BUSINESS SEGMENTS

8.4.4             PRODUCT PORTFOLIO

8.4.5             BUSINESS PERFORMANCE

8.4.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.5.           CELGENE CORPORATION

8.5.1             COMPANY OVERVIEW

8.5.2             COMPANY SNAPSHOT

8.5.3             OPERATING BUSINESS SEGMENTS

8.5.4             PRODUCT PORTFOLIO

8.5.5             BUSINESS PERFORMANCE

8.5.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.6.           F. HOFFMANN-LA ROCHE LTD.

8.6.1             COMPANY OVERVIEW

8.6.2             COMPANY SNAPSHOT

8.6.3             OPERATING BUSINESS SEGMENTS

8.6.4             PRODUCT PORTFOLIO

8.6.5             BUSINESS PERFORMANCE

8.6.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.7.           JOHNSON & JOHNSON

8.7.1             COMPANY OVERVIEW

8.7.2             COMPANY SNAPSHOT

8.7.3             OPERATING BUSINESS SEGMENTS

8.7.4             PRODUCT PORTFOLIO

8.7.5             BUSINESS PERFORMANCE

8.7.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.8.           MERCK & CO., INC.

8.8.1             COMPANY OVERVIEW

8.8.2             COMPANY SNAPSHOT

8.8.3             OPERATING BUSINESS SEGMENTS

8.8.4             PRODUCT PORTFOLIO

8.8.5             BUSINESS PERFORMANCE

8.8.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.9.           NOVARTIS AG

8.9.1             COMPANY OVERVIEW

8.9.2             COMPANY SNAPSHOT

8.9.3             OPERATING BUSINESS SEGMENTS

8.9.4             PRODUCT PORTFOLIO

8.9.5             BUSINESS PERFORMANCE

8.9.6             KEY STRATEGIC MOVES AND DEVELOPMENT

8.10.         PFIZER INC.

8.10.1           COMPANY OVERVIEW

8.10.2           COMPANY SNAPSHOT

8.10.3           OPERATING BUSINESS SEGMENTS

8.10.4           PRODUCT PORTFOLIO

8.10.5           BUSINESS PERFORMANCE

8.10.6           KEY STRATEGIC MOVES AND DEVELOPMENT

LIST OF TABLES

TABLE 1. GLOBAL  CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 2. CHEMOTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 3. NORTH AMERICA CHEMOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 4. EUROPE CHEMOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 5. ASIA-PACIFIC CHEMOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 6. REST OF WORLD CHEMOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 7. TARGETED THERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 8. NORTH AMERICA TARGETED THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 9. EUROPE TARGETED THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 10. ASIA-PACIFIC TARGETED THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 11. REST OF WORLD TARGETED THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 12. IMMUNOTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 13. NORTH AMERICA IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 14. EUROPE IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 15. ASIA-PACIFIC IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 16. REST OF WORLD IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 17. HORMONAL THERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 18. NORTH AMERICA HORMONAL THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 19. EUROPE HORMONAL THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 20. ASIA-PACIFIC HORMONAL THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 21. REST OF WORLD HORMONAL THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 22. GLOBAL 0 MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 23. PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 24. NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 25. EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 26. ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 27. REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 28. CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 29. NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 30. EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 31. ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 32. REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 33. CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 34. NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 35. EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 36. ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 37. REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 38. GLOBAL  CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 39. LUNG CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 40. NORTH AMERICA LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 41. EUROPE LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 42. ASIA-PACIFIC LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 43. REST OF WORLD LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 44. STOMACH CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 45. NORTH AMERICA STOMACH CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 46. EUROPE STOMACH CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 47. ASIA-PACIFIC STOMACH CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 48. REST OF WORLD STOMACH CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 49. COLORECTAL CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 50. NORTH AMERICA COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 51. EUROPE COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 52. ASIA-PACIFIC COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 53. REST OF WORLD COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 54. BREAST CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 55. NORTH AMERICA BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 56. EUROPE BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 57. ASIA-PACIFIC BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 58. REST OF WORLD BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 59. PROSTATE CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 60. NORTH AMERICA PROSTATE CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 61. EUROPE PROSTATE CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 62. ASIA-PACIFIC PROSTATE CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 63. REST OF WORLD PROSTATE CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 64. GLOBAL LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 65. HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 66. NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 67. EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 68. ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 69. REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 70. VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 71. NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 72. EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 73. ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 74. REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 75. OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 76. NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 77. EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 78. ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 79. REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 80. LIVER CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 81. NORTH AMERICA LIVER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 82. EUROPE LIVER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 83. ASIA-PACIFIC LIVER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 84. REST OF WORLD LIVER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 85. ESOPHAGUS CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 86. NORTH AMERICA ESOPHAGUS CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 87. EUROPE ESOPHAGUS CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 88. ASIA-PACIFIC ESOPHAGUS CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 89. REST OF WORLD ESOPHAGUS CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 90. CERVICAL CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 91. NORTH AMERICA CERVICAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 92. EUROPE CERVICAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 93. ASIA-PACIFIC CERVICAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 94. REST OF WORLD CERVICAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 95. KIDNEY CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 96. NORTH AMERICA KIDNEY CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 97. EUROPE KIDNEY CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 98. ASIA-PACIFIC KIDNEY CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 99. REST OF WORLD KIDNEY CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 100. BLADDER CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 101. NORTH AMERICA BLADDER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 102. EUROPE BLADDER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 103. ASIA-PACIFIC BLADDER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 104. REST OF WORLD BLADDER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 105. GLOBAL  CANCER DRUGS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 106. NORTH AMERICA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 107. NORTH AMERICA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 108. NORTH AMERICA  LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 109. U.S. CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 110. U.S. CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 111. U.S. LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 112. CANADA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 113. CANADA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 114. CANADA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 115. MEXICO CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 116. MEXICO CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 117. MEXICO LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 118. EUROPE CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 119. EUROPE CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 120. EUROPE  LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 121. GERMANY CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 122. GERMANY CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 123. GERMANY LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 124. UK CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 125. UK CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 126. UK LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 127. FRANCE CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 128. FRANCE CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 129. FRANCE LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 130. SPAIN CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 131. SPAIN CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 132. SPAIN LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 133. ITALY CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 134. ITALY CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 135. ITALY LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 136. REST OF EUROPE CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 137. REST OF EUROPE CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 138. REST OF EUROPE LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 139. ASIA-PACIFIC CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 140. ASIA-PACIFIC CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 141. ASIA-PACIFIC  LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 142. JAPAN CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 143. JAPAN CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 144. JAPAN LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 145. INDIA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 146. INDIA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 147. INDIA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 148. CHINA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 149. CHINA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 150. CHINA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 151. SOUTH KOREA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 152. SOUTH KOREA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 153. SOUTH KOREA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 154. AUSTRALIA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 155. AUSTRALIA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 156. AUSTRALIA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 157. REST OF ASIA-PACIFIC CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 158. REST OF ASIA-PACIFIC CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 159. REST OF ASIA-PACIFIC LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 160. REST OF WORLD CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 161. REST OF WORLD CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 162. REST OF WORLD  LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 163. BRAZIL CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 164. BRAZIL CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 165. BRAZIL LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 166. SAUDI ARABIA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 167. SAUDI ARABIA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 168. SAUDI ARABIA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 169. SOUTH AFRICA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 170. SOUTH AFRICA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 171. SOUTH AFRICA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 172. REMAINING COUNTRIES CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

TABLE 173. REMAINING COUNTRIES CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 174. REMAINING COUNTRIES LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

TABLE 175. ABBVIE INC.: COMPANY SNAPSHOT

TABLE 176. ABBVIE INC.: OPERATING SEGMENTS

TABLE 177. ABBVIE INC.: PRODUCT PORTFOLIO

TABLE 178. ABBVIE INC.: KEY STRATERGY

TABLE 179. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT

TABLE 180. ASTELLAS PHARMA INC.: OPERATING SEGMENTS

TABLE 181. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO

TABLE 182. ASTELLAS PHARMA INC.: KEY STRATERGY

TABLE 183. ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 184. ASTRAZENECA PLC: OPERATING SEGMENTS

TABLE 185. ASTRAZENECA PLC: PRODUCT PORTFOLIO

TABLE 186. ASTRAZENECA PLC: KEY STRATERGY

TABLE 187. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

TABLE 188. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS

TABLE 189. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

TABLE 190. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGY

TABLE 191. CELGENE CORPORATION: COMPANY SNAPSHOT

TABLE 192. CELGENE CORPORATION: OPERATING SEGMENTS

TABLE 193. CELGENE CORPORATION: PRODUCT PORTFOLIO

TABLE 194. CELGENE CORPORATION: KEY STRATERGY

TABLE 195. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 196. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS

TABLE 197. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 198. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGY

TABLE 199. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 200. JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 201. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 202. JOHNSON & JOHNSON: KEY STRATERGY

TABLE 203. MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 204. MERCK & CO., INC.: OPERATING SEGMENTS

TABLE 205. MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 206. MERCK & CO., INC.: KEY STRATERGY

TABLE 207. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 208. NOVARTIS AG: OPERATING SEGMENTS

TABLE 209. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 210. NOVARTIS AG: KEY STRATERGY

TABLE 211. PFIZER INC.: COMPANY SNAPSHOT

TABLE 212. PFIZER INC.: OPERATING SEGMENTS

TABLE 213. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 214. PFIZER INC.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. GLOBAL  CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 2. CHEMOTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 3. NORTH AMERICA CHEMOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 4. EUROPE CHEMOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 5. ASIA-PACIFIC CHEMOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 6. REST OF WORLD CHEMOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 7. TARGETED THERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 8. NORTH AMERICA TARGETED THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 9. EUROPE TARGETED THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 10. ASIA-PACIFIC TARGETED THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 11. REST OF WORLD TARGETED THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 12. IMMUNOTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 13. NORTH AMERICA IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 14. EUROPE IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 15. ASIA-PACIFIC IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 16. REST OF WORLD IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 17. HORMONAL THERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 18. NORTH AMERICA HORMONAL THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 19. EUROPE HORMONAL THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 20. ASIA-PACIFIC HORMONAL THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 21. REST OF WORLD HORMONAL THERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 22. GLOBAL 0 MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 23. PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 24. NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 25. EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 26. ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 27. REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 28. CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 29. NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 30. EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 31. ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 32. REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 33. CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 34. NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 35. EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 36. ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 37. REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 38. GLOBAL  CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 39. LUNG CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 40. NORTH AMERICA LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 41. EUROPE LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 42. ASIA-PACIFIC LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 43. REST OF WORLD LUNG CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 44. STOMACH CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 45. NORTH AMERICA STOMACH CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 46. EUROPE STOMACH CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 47. ASIA-PACIFIC STOMACH CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 48. REST OF WORLD STOMACH CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 49. COLORECTAL CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 50. NORTH AMERICA COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 51. EUROPE COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 52. ASIA-PACIFIC COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 53. REST OF WORLD COLORECTAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 54. BREAST CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 55. NORTH AMERICA BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 56. EUROPE BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 57. ASIA-PACIFIC BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 58. REST OF WORLD BREAST CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 59. PROSTATE CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 60. NORTH AMERICA PROSTATE CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 61. EUROPE PROSTATE CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 62. ASIA-PACIFIC PROSTATE CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 63. REST OF WORLD PROSTATE CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 64. GLOBAL LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 65. HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 66. NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 67. EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 68. ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 69. REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 70. VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 71. NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 72. EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 73. ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 74. REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 75. OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 76. NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 77. EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 78. ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 79. REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 80. LIVER CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 81. NORTH AMERICA LIVER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 82. EUROPE LIVER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 83. ASIA-PACIFIC LIVER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 84. REST OF WORLD LIVER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 85. ESOPHAGUS CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 86. NORTH AMERICA ESOPHAGUS CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 87. EUROPE ESOPHAGUS CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 88. ASIA-PACIFIC ESOPHAGUS CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 89. REST OF WORLD ESOPHAGUS CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 90. CERVICAL CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 91. NORTH AMERICA CERVICAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 92. EUROPE CERVICAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 93. ASIA-PACIFIC CERVICAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 94. REST OF WORLD CERVICAL CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 95. KIDNEY CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 96. NORTH AMERICA KIDNEY CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 97. EUROPE KIDNEY CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 98. ASIA-PACIFIC KIDNEY CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 99. REST OF WORLD KIDNEY CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 100. BLADDER CANCER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 101. NORTH AMERICA BLADDER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 102. EUROPE BLADDER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 103. ASIA-PACIFIC BLADDER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 104. REST OF WORLD BLADDER CANCER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 105. GLOBAL  CANCER DRUGS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 106. NORTH AMERICA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 107. NORTH AMERICA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 108. NORTH AMERICA  LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 109. U.S. CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 110. U.S. CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 111. U.S. LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 112. CANADA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 113. CANADA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 114. CANADA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 115. MEXICO CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 116. MEXICO CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 117. MEXICO LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 118. EUROPE CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 119. EUROPE CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 120. EUROPE  LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 121. GERMANY CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 122. GERMANY CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 123. GERMANY LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 124. UK CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 125. UK CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 126. UK LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 127. FRANCE CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 128. FRANCE CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 129. FRANCE LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 130. SPAIN CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 131. SPAIN CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 132. SPAIN LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 133. ITALY CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 134. ITALY CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 135. ITALY LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 136. REST OF EUROPE CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 137. REST OF EUROPE CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 138. REST OF EUROPE LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 139. ASIA-PACIFIC CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 140. ASIA-PACIFIC CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 141. ASIA-PACIFIC  LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 142. JAPAN CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 143. JAPAN CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 144. JAPAN LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 145. INDIA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 146. INDIA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 147. INDIA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 148. CHINA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 149. CHINA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 150. CHINA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 151. SOUTH KOREA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 152. SOUTH KOREA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 153. SOUTH KOREA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 154. AUSTRALIA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 155. AUSTRALIA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 156. AUSTRALIA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 157. REST OF ASIA-PACIFIC CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 158. REST OF ASIA-PACIFIC CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 159. REST OF ASIA-PACIFIC LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 160. REST OF WORLD CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 161. REST OF WORLD CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 162. REST OF WORLD  LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 163. BRAZIL CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 164. BRAZIL CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 165. BRAZIL LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 166. SAUDI ARABIA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 167. SAUDI ARABIA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 168. SAUDI ARABIA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 169. SOUTH AFRICA CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 170. SOUTH AFRICA CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 171. SOUTH AFRICA LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 172. REMAINING COUNTRIES CANCER DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2022-2030, MILLION USD

FIGURE 173. REMAINING COUNTRIES CANCER DRUGS MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 174. REMAINING COUNTRIES LIVER CANCER MARKET VALUE, BY INDICATION, 2022-2030, MILLION USD

FIGURE 175. ABBVIE INC.: NET SALES,2017-2019

FIGURE 176. ASTELLAS PHARMA INC.: NET SALES,2017-2019

FIGURE 177. ASTRAZENECA PLC: NET SALES,2017-2019

FIGURE 178. BRISTOL-MYERS SQUIBB COMPANY: NET SALES,2017-2019

FIGURE 179. CELGENE CORPORATION: NET SALES,2017-2019

FIGURE 180. F. HOFFMANN-LA ROCHE LTD.: NET SALES,2017-2019

FIGURE 181. JOHNSON & JOHNSON: NET SALES,2017-2019

FIGURE 182. MERCK & CO., INC.: NET SALES,2017-2019

FIGURE 183. NOVARTIS AG: NET SALES,2017-2019

FIGURE 184. PFIZER INC.: NET SALES,2017-2019

KEY PLAYERS:

  • Astellas Pharma Inc.

  • AbbVie Inc.

  • Bristol-Myers Squibb Company

  • AstraZeneca PLC

  • F. Hoffmann-La Roche ltd.

  • Celgene Corporation

  • Merck & Co., Inc.

  • Johnson & Johnson (Janssen Global Services, LLC,)

  • Pfizer Inc.

  • Novartis AG


Frequently Asked Questions
What will be the worth of global Cancer Drug Market by the end of 2030?

According to the report published by Next Move Strategy Consulting, the Cancer Drug market business is expected to hit at $215.11 billion (USD) by 2030.

Which region is expected to hold the highest market share in the Cancer Drug Market?

North America is expected to hold the highest market share in the global market. The region is expected to witness remarkable growth as it houses the major key players in the market.

Which are the top companies in the Cancer Drug industry?

Astellas Pharma Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, f. Hoffmann-La Roche ltd., Celgene Corporation, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC,), Pfizer Inc., Novartis AG

What are the market segmentations and scope of the study?

The global Cancer Drug market share is analyzed on the basis of drug class, indication and geography.

How big is the Cancer Drug Market?

Currently (in 2019), the market value stands at USD 112.73 billion and it is anticipated to reach USD 215.11 billion by 2030.